Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

tyrosine kinase inhibitor

  • You have access
    Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
    Michael C. Kreissl, Marcel J.R. Janssen and James Nagarajah
    Journal of Nuclear Medicine January 1, 2019, 60 (1) 9-15; DOI: https://doi.org/10.2967/jnumed.117.190819
  • You have access
    Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging
    Longguang Tang, Chenyu Peng, Bowen Tang, Zijing Li, Xiangyu Wang, Jindian Li, Fei Gao, Lumei Huang, Duo Xu, Pu Zhang, Rongqiang Zhuang, Xinhui Su, Xiaoyuan Chen and Xianzhong Zhang
    Journal of Nuclear Medicine September 1, 2018, 59 (9) 1386-1391; DOI: https://doi.org/10.2967/jnumed.117.205088
  • You have access
    Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
    Rudolf A. Werner, Jan-Stefan Schmid, Takahiro Higuchi, Mehrbod S. Javadi, Steven P. Rowe, Bruno Märkl, Christoph Aulmann, Martin Fassnacht, Matthias Kroiss, Christoph Reiners, Andreas K. Buck, Michael C. Kreissl and Constantin Lapa
    Journal of Nuclear Medicine May 1, 2018, 59 (5) 756-761; DOI: https://doi.org/10.2967/jnumed.117.199778
  • You have access
    Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
    Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders and Wim J.G. Oyen
    Journal of Nuclear Medicine February 1, 2014, 55 (2) 242-247; DOI: https://doi.org/10.2967/jnumed.113.131110
  • You have access
    Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer
    Philip J. Saylor, Umar Mahmood, Anchisa Kunawudhi, Matthew R. Smith, Edwin L. Palmer and M. Dror Michaelson
    Journal of Nuclear Medicine November 1, 2012, 53 (11) 1670-1675; DOI: https://doi.org/10.2967/jnumed.112.105007
SNMMI

© 2025 SNMMI

Powered by HighWire